Relmada Jumps as Jefferies Upgrades on a Potential Turnaround Story
Jefferies Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $13
Jefferies analyst Andrew Tsai initiates coverage on $Relmada Therapeutics(RLMD.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 55
Relmada Therapeutics Analyst Ratings
Express News | Relmada Therapeutics Inc : Jefferies Raises Target Price to $13 From $3.5
Express News | Relmada Therapeutics Inc : Jefferies Raises to Buy From Hold
Sergio Traversa Bought 57% More Shares In Relmada Therapeutics
Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares
Relmada Therapeutics Insider Bought Shares Worth $395,115, According to a Recent SEC Filing
Express News | Relmada Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing
Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q2 2024 Earnings Conference
Optimistic Outlook for Relmada Therapeutics: Strategic Trial Enhancements and Solid Financial Position
Relmada Therapeutics Shares Are Trading Lower. The Company Reported Q2 Financial Results.
Express News | Relmada Therapeutics Inc : Jefferies Cuts Target Price to $3.50 From $5.50
Express News | Relmada Therapeutics Inc: Cash Position of $70.4 Mln Provides Runway Through Key Milestones, Into 2025
Relmada Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update